Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Cash & Equivalents (2023 - 2026)

Alto Neuroscience has reported Cash & Equivalents over the past 4 years, most recently at $263.8 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $263.8 million for Q1 2026, up 64.08% from a year ago — trailing twelve months through Mar 2026 was $263.8 million (up 64.08% YoY), and the annual figure for FY2025 was $176.5 million, up 4.93%.
  • Cash & Equivalents reached $263.8 million in Q1 2026 per ANRO's latest filing, up from $176.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $263.8 million in Q1 2026 and bottomed at $82.5 million in Q4 2023.
  • Median Cash & Equivalents over the past 4 years was $172.3 million (2024), compared with a mean of $171.8 million.
  • The largest annual shift saw Cash & Equivalents surged 103.88% in 2024 before it fell 24.15% in 2025.
  • Over 4 years, Cash & Equivalents stood at $82.5 million in 2023, then soared by 103.88% to $168.2 million in 2024, then grew by 4.93% to $176.5 million in 2025, then skyrocketed by 49.45% to $263.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for ANRO at $263.8 million in Q1 2026, $176.5 million in Q4 2025, and $137.8 million in Q3 2025.